Fortuitous Discovery of Asymptomatic Homozygous Antithrombin Deficiency: A Rare p.Leu131Phe Heparin‐Binding Site Mutation: A Case Report

ABSTRACT Homozygous Type II heparin‐binding site antithrombin deficiency is a rare inherited thrombophilia associated with a high risk of early thrombotic events. We report a 6‐week‐old infant homozygous for the SERPINC1 c.391C>T (p.Leu131Phe) variant (Antithrombin Budapest III), with markedly reduced antithrombin activity (12%). Despite this high‐risk genotype, the patient remains asymptomatic without thrombotic or vascular abnormalities and has not required anticoagulant treatment to date. This case highlights the phenotypic heterogeneity of homozygous antithrombin Budapest III deficiency and the importance of genetic diagnosis, family screening, and careful long‐term follow‐up. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-11-07
DOI
https://doi.org/10.1002/jha2.70398
Primary Topic
Blood Coagulation and Thrombosis Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fortuitous Discovery of Asymptomatic Homozygous Antithrombin Deficiency: A Rare p.Leu131Phe Heparin‐Binding Site Mutation: A Case Report

Laurence Rozen, Christelle Orlando, Anne Demulder, Sara Cherkaoui et al.
1 links
eJHaem
Blood Coagulation and Thrombosis Mechanisms
article

Fortuitous Discovery of Asymptomatic Homozygous Antithrombin Deficiency: A Rare p.Leu131Phe Heparin‐Binding Site Mutation: A Case Report

Laurence Rozen, Christelle Orlando, Anne Demulder, Sara Cherkaoui, Laurence Dedeken, Joanna Simar
article en

Abstract

ABSTRACT Homozygous Type II heparin‐binding site antithrombin deficiency is a rare inherited thrombophilia associated with a high risk of early thrombotic events. We report a 6‐week‐old infant homozygous for the SERPINC1 c.391C>T (p.Leu131Phe) variant (Antithrombin Budapest III), with markedly reduced antithrombin activity (12%). Despite this high‐risk genotype, the patient remains asymptomatic without thrombotic or vascular abnormalities and has not required anticoagulant treatment to date. This case highlights the phenotypic heterogeneity of homozygous antithrombin Budapest III deficiency and the importance of genetic diagnosis, family screening, and careful long‐term follow‐up. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

eJHaemVol. 7(6)
Université Libre de Bruxelles (BE), Vrije Universiteit Brussel (BE), Clinique Saint Pierre (BE), Centre Hospitalier Universitaire Brugmann (BE), Queen Fabiola Children's University Hospital (BE), Universitair Ziekenhuis Brussel (BE)
Good health and well-being
Openalex Percentile: Top 13%
Blood Coagulation and Thrombosis Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon